DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
ABACAVIR HYDROXYACETATE
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis
Unknown
ABACAVIR HYDROXYACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
B3C7MG354B
Molecule Type:
Small molecule
Molecular Formula:
C16H20N6O3
Molecular Weight:
344.38
AlogP:
0.64
PSA:
128.18
HBD:
3.0
HBA:
#RotB:
6.0
Source:
PLEVITREXED
2
Small molecule
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Unknown
PLEVITREXED
×
Maximum Phase:
2
First Approval:
None
UNII:
L9P2881C3H
Molecule Type:
Small molecule
Molecular Formula:
C26H25FN8O4
Molecular Weight:
532.54
AlogP:
2.06
PSA:
170.11
HBD:
4.0
HBA:
#RotB:
10.0
Source:
FORODESINE HCL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FORODESINE HCL
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MGCD265
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MGCD265
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APITOLISIB
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Non-Hodgkin; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Carcinoma, Renal Cell; Endometrial Neoplasms
PI3-kinase class I inhibitor
APITOLISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
1C854K1MIJ
Molecule Type:
Small molecule
Molecular Formula:
C23H30N8O3S
Molecular Weight:
498.61
AlogP:
0.9
PSA:
133.83
HBD:
2.0
HBA:
#RotB:
5.0
Source:
RO-24-7429
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 Tat protein antagonist
RO-24-7429
×
Maximum Phase:
2
First Approval:
None
UNII:
MLW2GKK8LI
Molecule Type:
Small molecule
Molecular Formula:
C14H13ClN4
Molecular Weight:
272.74
AlogP:
2.77
PSA:
52.54
HBD:
2.0
HBA:
#RotB:
1.0
Source:
SCH-900271
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Hydroxycarboxylic acid receptor 2 agonist
SCH-900271
×
Maximum Phase:
2
First Approval:
None
UNII:
G2283XQ6VJ
Molecule Type:
Small molecule
Molecular Formula:
C14H16N2O4
Molecular Weight:
276.29
AlogP:
1.29
PSA:
95.93
HBD:
2.0
HBA:
#RotB:
4.0
Source:
AFELETECAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
DNA topoisomerase I stabiliser
AFELETECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
IX0QAD6RD2
Molecule Type:
Small molecule
Molecular Formula:
C45H49N7O11S
Molecular Weight:
895.99
AlogP:
2.95
PSA:
237.48
HBD:
6.0
HBA:
#RotB:
13.0
Source:
BURAPITANT
2
Small molecule
Investigational
Unknown
Unknown
Urinary Bladder, Overactive
Neurokinin 1 receptor antagonist
BURAPITANT
×
Maximum Phase:
2
First Approval:
None
UNII:
E35SK332MS
Molecule Type:
Small molecule
Molecular Formula:
C31H35Cl2F6N3O3
Molecular Weight:
682.53
AlogP:
6.94
PSA:
75.87
HBD:
1.0
HBA:
#RotB:
8.0
Source:
DEUTARSERINE
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Unknown
DEUTARSERINE
×
Maximum Phase:
2
First Approval:
None
UNII:
OD54L0MH86
Molecule Type:
Small molecule
Molecular Formula:
C3H7NO3
Molecular Weight:
106.1
AlogP:
-1.61
PSA:
83.55
HBD:
3.0
HBA:
#RotB:
2.0
Source:
R-112
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Tyrosine-protein kinase SYK inhibitor
R-112
×
Maximum Phase:
2
First Approval:
None
UNII:
Y7W5AL9KHB
Molecule Type:
Small molecule
Molecular Formula:
C16H13FN4O2
Molecular Weight:
312.3
AlogP:
3.51
PSA:
90.3
HBD:
4.0
HBA:
#RotB:
4.0
Source:
ELTOPRAZINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ELTOPRAZINE
×
Maximum Phase:
2
First Approval:
None
UNII:
510M006KO6
Molecule Type:
Small molecule
Molecular Formula:
C12H16N2O2
Molecular Weight:
220.27
AlogP:
0.87
PSA:
33.73
HBD:
1.0
HBA:
#RotB:
1.0
Source:
REVAMILAST
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Asthma
Phosphodiesterase 4 inhibitor
REVAMILAST
×
Maximum Phase:
2
First Approval:
None
UNII:
30LE65637T
Molecule Type:
Small molecule
Molecular Formula:
C18H9Cl2F2N3O4
Molecular Weight:
440.19
AlogP:
4.77
PSA:
91.3
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ALAGEBRIUM CHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Cardiovascular Diseases; Heart Failure; Hypertension
Unknown
ALAGEBRIUM CHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
79QS8K2877
Molecule Type:
Small molecule
Molecular Formula:
C13H14ClNOS
Molecular Weight:
267.78
AlogP:
2.54
PSA:
20.95
HBD:
0.0
HBA:
#RotB:
3.0
Source:
FULACIMSTAT
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Heart Failure; Myocardial Infarction
Chymase inhibitor
FULACIMSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
VIR72PP4ZU
Molecule Type:
Small molecule
Molecular Formula:
C23H16F3N3O6
Molecular Weight:
487.39
AlogP:
2.7
PSA:
116.44
HBD:
1.0
HBA:
#RotB:
3.0
Source:
ACRIDINE
2
Small molecule
Investigational
Unknown
Unknown
Central Nervous System Neoplasms; Lung Neoplasms
DNA disrupting agent
ACRIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
42NI1P5Q1X
Molecule Type:
Small molecule
Molecular Formula:
C13H9N
Molecular Weight:
179.22
AlogP:
3.39
PSA:
12.89
HBD:
0.0
HBA:
#RotB:
0.0
Source:
ROVAZOLAC
2
Small molecule
Investigational
Unknown
Unknown
Dermatitis, Atopic
Liver X receptor agonist
ROVAZOLAC
×
Maximum Phase:
2
First Approval:
None
UNII:
W51K389XIL
Molecule Type:
Small molecule
Molecular Formula:
C21H19F3N2O4S
Molecular Weight:
452.45
AlogP:
4.2
PSA:
78.26
HBD:
0.0
HBA:
#RotB:
6.0
Source:
LY2828360
2
Small molecule
Investigational
Unknown
Unknown
Osteoarthritis, Knee
Cannabinoid CB2 receptor agonist
LY2828360
×
Maximum Phase:
2
First Approval:
None
UNII:
O12H7VFU6P
Molecule Type:
Small molecule
Molecular Formula:
C22H27ClN6O
Molecular Weight:
426.95
AlogP:
3.56
PSA:
59.31
HBD:
0.0
HBA:
#RotB:
3.0
Source:
LISOFYLLINE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1
Unknown
LISOFYLLINE
×
Maximum Phase:
2
First Approval:
None
UNII:
L1F2Q2X956
Molecule Type:
Small molecule
Molecular Formula:
C13H20N4O3
Molecular Weight:
280.33
AlogP:
-0.02
PSA:
82.05
HBD:
1.0
HBA:
#RotB:
5.0
Source:
CELGOSIVIR
2
Small molecule
Investigational
Unknown
Unknown
Dengue; Hepatitis C, Chronic
Alpha glucosidase inhibitor
CELGOSIVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
895VG117HN
Molecule Type:
Small molecule
Molecular Formula:
C12H21NO5
Molecular Weight:
259.3
AlogP:
-1.13
PSA:
90.23
HBD:
3.0
HBA:
#RotB:
3.0
Source:
REBOXETINE MESYLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
REBOXETINE MESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
L94J81YNNY
Molecule Type:
Small molecule
Molecular Formula:
C20H27NO6S
Molecular Weight:
409.5
AlogP:
3.19
PSA:
39.72
HBD:
1.0
HBA:
#RotB:
6.0
Source:
BEDORADRINE SULFATE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive; Asthma; Status Asthmaticus
Beta-2 adrenergic receptor agonist
BEDORADRINE SULFATE
×
Maximum Phase:
2
First Approval:
None
UNII:
P875C0DV2V
Molecule Type:
Small molecule
Molecular Formula:
C48H66N4O14S
Molecular Weight:
955.14
AlogP:
1.57
PSA:
102.26
HBD:
4.0
HBA:
#RotB:
9.0
Source:
ALBITIAZOLIUM BROMIDE
2
Small molecule
Investigational
Unknown
Unknown
Malaria
Unknown
ALBITIAZOLIUM BROMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
3AC0AJ4ILP
Molecule Type:
Small molecule
Molecular Formula:
C24H42Br2N2O2S2
Molecular Weight:
614.55
AlogP:
4.67
PSA:
48.22
HBD:
2.0
HBA:
#RotB:
17.0
Source:
SUCRALOSE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
SUCRALOSE
×
Maximum Phase:
2
First Approval:
None
UNII:
96K6UQ3ZD4
Molecule Type:
Small molecule
Molecular Formula:
C12H19Cl3O8
Molecular Weight:
397.64
AlogP:
-1.66
PSA:
128.84
HBD:
5.0
HBA:
#RotB:
5.0
Source:
AZD-1236
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis; Pulmonary Disease, Chronic Obstructive
Matrix metalloproteinase 12 inhibitor
AZD-1236
×
Maximum Phase:
2
First Approval:
None
UNII:
B4OQY51WZS
Molecule Type:
Small molecule
Molecular Formula:
C15H19ClN4O5S
Molecular Weight:
402.86
AlogP:
0.51
PSA:
117.7
HBD:
2.0
HBA:
#RotB:
5.0
Source:
NETOGLITAZONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Peroxisome proliferator-activated receptor gamma modulator
NETOGLITAZONE
×
Maximum Phase:
2
First Approval:
None
UNII:
QOV2JZ647A
Molecule Type:
Small molecule
Molecular Formula:
C21H16FNO3S
Molecular Weight:
381.43
AlogP:
4.45
PSA:
55.4
HBD:
1.0
HBA:
#RotB:
5.0
Source:
AFABICIN
2
Small molecule
Investigational
Unknown
Unknown
Infections
Enoyl-[acyl-carrier-protein] reductase (FabI) inhibitor
AFABICIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DMM8663H2R
Molecule Type:
Small molecule
Molecular Formula:
C23H24N3O7P
Molecular Weight:
485.43
AlogP:
3.15
PSA:
133.41
HBD:
2.0
HBA:
#RotB:
7.0
Source:
BMS-582949
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Psoriasis; Vascular Diseases
MAP kinase p38 alpha inhibitor
BMS-582949
×
Maximum Phase:
2
First Approval:
None
UNII:
CR743OME9E
Molecule Type:
Small molecule
Molecular Formula:
C22H26N6O2
Molecular Weight:
406.49
AlogP:
3.12
PSA:
100.42
HBD:
3.0
HBA:
#RotB:
7.0
Source:
GEMCABENE
2
Small molecule
Investigational
Unknown
Unknown
Hypercholesterolemia; Lipid Metabolism Disorders; Non-alcoholic Fatty Liver Disease
Unknown
GEMCABENE
×
Maximum Phase:
2
First Approval:
None
UNII:
B96UX1DDKS
Molecule Type:
Small molecule
Molecular Formula:
C16H30O5
Molecular Weight:
302.41
AlogP:
3.57
PSA:
83.83
HBD:
2.0
HBA:
#RotB:
12.0
Source:
ASP8273
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ASP8273
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-986020
2
Small molecule
Investigational
Unknown
Unknown
Idiopathic Pulmonary Fibrosis; Scleroderma, Localized
Lysophosphatidic acid receptor Edg-2 antagonist
BMS-986020
×
Maximum Phase:
2
First Approval:
None
UNII:
38CTP01B4L
Molecule Type:
Small molecule
Molecular Formula:
C29H26N2O5
Molecular Weight:
482.54
AlogP:
6.74
PSA:
101.66
HBD:
2.0
HBA:
#RotB:
7.0
Source:
LYSERGIDE
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Anxiety; Depressive Disorder, Major; Pain
Unknown
LYSERGIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
8NA5SWF92O
Molecule Type:
Small molecule
Molecular Formula:
C20H25N3O
Molecular Weight:
323.44
AlogP:
2.91
PSA:
39.34
HBD:
1.0
HBA:
#RotB:
3.0
Source:
RIPASUDIL
2
Small molecule
Investigational
Unknown
Unknown
Retinopathy of Prematurity; Corneal Edema; Fuchs' Endothelial Dystrophy; Glaucoma
Rho-associated protein kinase inhibitor
RIPASUDIL
×
Maximum Phase:
2
First Approval:
None
UNII:
11978226XX
Molecule Type:
Small molecule
Molecular Formula:
C15H18FN3O2S
Molecular Weight:
323.39
AlogP:
1.75
PSA:
62.3
HBD:
1.0
HBA:
#RotB:
2.0
Source:
TAPRENEPAG ISOPROPYL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Prostanoid EP2 receptor agonist
TAPRENEPAG ISOPROPYL
×
Maximum Phase:
2
First Approval:
None
UNII:
81LDP7XIYG
Molecule Type:
Small molecule
Molecular Formula:
C27H28N4O5S
Molecular Weight:
520.61
AlogP:
3.99
PSA:
103.62
HBD:
0.0
HBA:
#RotB:
11.0
Source:
LOMIBUVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
RNA-directed RNA polymerase negative allosteric modulator
LOMIBUVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
37L2LF4A2D
Molecule Type:
Small molecule
Molecular Formula:
C25H35NO4S
Molecular Weight:
445.63
AlogP:
5.31
PSA:
77.84
HBD:
2.0
HBA:
#RotB:
4.0
Source:
1
2
…
131
132
133
134
135
136
137
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA